CVS Health Seeks Return To LDL Treatment Targets To Control PCSK9s
This article was originally published in The Pink Sheet Daily
Executive Summary
Broad nature of latest cholesterol treatment guidelines makes it hard to deploy utilization management programs to control use of pricey new PCSK9 inhibitors, CVS Health argues in JAMA editorial.
You may also be interested in...
PCSK9 Coverage: Payers Wrestling With Proving Statin Intolerance
Confirmation of statin intolerance is likely to be among extensive prior authorization requirements that must be satisfied before payers approve coverage for the new class of cholesterol-lowering drugs.
Praluent Coverage: Being First May Not Matter As Payers Await Repatha
The pricing advantage that might have been available to Praluent as first-in-class is undercut by the fact that it only has about a month’s lead time over the competition.
Praluent Launch Brings Clinical Practice Challenges
Despite enthusiasm about PCSK9 class, the prescribing community will have to wrestle with patient-selection criteria, uncertainty about very low LDL levels and a lack of outcomes data for Sanofi and Regeneron’s alirocumab.